title: [Rheumatoid arthritis. Systemic inflammation and cardiovascular morbidity].
abstract: In recent years it could be shown that systemic inflammation, which typically occurs in chronic inflammatory rheumatic diseases, significantly contributes to cardiovascular morbidity and mortality. All rheumatic diseases inherit this enhanced risk for cardiovascular complications with rheumatoid arthritis being one of the most prominent. As the underlying pathophysiological mechanisms are very similar with respect to endothelial damage all rheumatic diseases and specifically rheumatoid arthritis should be monitored and treated with disease-modifying drugs and biological agents as consistently as possible to be able to improve the long-term outcome of affected patients as much as possible.
authors: Abteilung für Rheumatologie und klinische Immunologie, Kerckhoff-Klinik GmbH, Benekestr. 2-8, 61231 Bad Nauhei. e.decker@kerckhoff-klinik.de
authors: E
authors: E
authors: Decker
authors: U
authors: U
authors: Müller-Ladner
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D002318:Cardiovascular Diseases / Q000150:complications / Q000175:diagnosis* / Q000628:therapy*; D003937:Diagnosis, Differential; D006801:Humans; D018746:Systemic Inflammatory Response Syndrome / Q000175:diagnosis* / Q000628:therapy*
chemical_list: D018501:Antirheumatic Agents